{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:41:24Z","timestamp":1790214084969,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s12282-020-01075-2","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T08:02:40Z","timestamp":1583481760000},"page":"765-775","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["miR-485-5p inhibits the progression of breast cancer cells by negatively regulating MUC1"],"prefix":"10.1007","volume":"27","author":[{"given":"Xiaowen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanye","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,6]]},"reference":[{"issue":"6","key":"1075_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3322\/caac.21412","volume":"67","author":"CE DeSantis","year":"2017","unstructured":"DeSantis CE, et al. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67(6):439\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"7661","key":"1075_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature22992","volume":"547","author":"E Rheinbay","year":"2017","unstructured":"Rheinbay E, et al. Recurrent and functional regulatory mutations in breast cancer. Nature. 2017;547(7661):55\u201360.","journal-title":"Nature"},{"key":"1075_CR3","doi-asserted-by":"publisher","first-page":"15004","DOI":"10.1038\/sigtrans.2015.4","volume":"1","author":"Y Peng","year":"2016","unstructured":"Peng Y, Croce CM. The role of microRNAs in human cancer. Signal Transduct Target Ther. 2016;1:15004.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"1075_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3109\/10409238.2015.1117054","volume":"51","author":"A Hata","year":"2016","unstructured":"Hata A, Kashima R. Dysregulation of microRNA biogenesis machinery in cancer. Crit Rev Biochem Mol Biol. 2016;51(3):121\u201334.","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"17","key":"1075_CR5","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1056\/NEJMp058190","volume":"353","author":"CZ Chen","year":"2005","unstructured":"Chen CZ. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med. 2005;353(17):1768\u201371.","journal-title":"N Engl J Med"},{"issue":"1","key":"1075_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3892\/ijmm.2017.2992","volume":"40","author":"XJ Lin","year":"2017","unstructured":"Lin XJ, et al. hsa-miR-485-5p reverses epithelial to mesenchymal transition and promotes cisplatin-induced cell death by targeting PAK1 in oral tongue squamous cell carcinoma. Int J Mol Med. 2017;40(1):83\u20139.","journal-title":"Int J Mol Med"},{"key":"1075_CR7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12935-017-0462-2","volume":"17","author":"J Duan","year":"2017","unstructured":"Duan J, et al. The role of miR-485-5p\/NUDT1 axis in gastric cancer. Cancer Cell Int. 2017;17:92.","journal-title":"Cancer Cell Int"},{"issue":"8","key":"1075_CR8","first-page":"1516","volume":"20","author":"LL Jing","year":"2016","unstructured":"Jing LL, Mo XM. Reduced miR-485-5p expression predicts poor prognosis in patients with gastric cancer. Eur Rev Med Pharmacol Sci. 2016;20(8):1516\u201320.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"11","key":"1075_CR9","first-page":"2212","volume":"7","author":"M Kang","year":"2015","unstructured":"Kang M, et al. miR-485-5p acts as a negative regulator in gastric cancer progression by targeting flotillin-1. Am J Transl Res. 2015;7(11):2212\u201322.","journal-title":"Am J Transl Res"},{"key":"1075_CR10","doi-asserted-by":"publisher","first-page":"e2159","DOI":"10.1038\/cddis.2016.27","volume":"7","author":"C Lou","year":"2016","unstructured":"Lou C, et al. MiR-485-3p and miR-485-5p suppress breast cancer cell metastasis by inhibiting PGC-1alpha expression. Cell Death Dis. 2016;7:e2159.","journal-title":"Cell Death Dis"},{"issue":"12","key":"1075_CR11","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/nrc2761","volume":"9","author":"DW Kufe","year":"2009","unstructured":"Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009;9(12):874\u201385.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"1075_CR12","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1093\/annonc\/mdt162","volume":"24","author":"BV Sinn","year":"2013","unstructured":"Sinn BV, et al. Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer. Ann Oncol. 2013;24(9):2316\u201324.","journal-title":"Ann Oncol"},{"issue":"4","key":"1075_CR13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10585-015-9711-8","volume":"32","author":"L Haddon","year":"2015","unstructured":"Haddon L, Hugh J. MUC1-mediated motility in breast cancer: a review highlighting the role of the MUC1\/ICAM-1\/Src signaling triad. Clin Exp Metastasis. 2015;32(4):393\u2013403.","journal-title":"Clin Exp Metastasis"},{"issue":"1","key":"1075_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/bjh.13245","volume":"169","author":"L Carmon","year":"2015","unstructured":"Carmon L, et al. Phase I\/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients. Br J Haematol. 2015;169(1):44\u201356.","journal-title":"Br J Haematol"},{"issue":"1","key":"1075_CR15","doi-asserted-by":"publisher","first-page":"e85400","DOI":"10.1371\/journal.pone.0085400","volume":"9","author":"R Kovjazin","year":"2014","unstructured":"Kovjazin R, et al. Cell surface-associated anti-MUC1-derived signal peptide antibodies: implications for cancer diagnostics and therapy. PLoS ONE. 2014;9(1):e85400.","journal-title":"PLoS ONE"},{"issue":"6","key":"1075_CR16","doi-asserted-by":"publisher","first-page":"e0179098","DOI":"10.1371\/journal.pone.0179098","volume":"12","author":"G Goode","year":"2017","unstructured":"Goode G, et al. Correction: MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer. PLoS ONE. 2017;12(6):e0179098.","journal-title":"PLoS ONE"},{"issue":"7","key":"1075_CR17","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1586\/1744666X.2014.916211","volume":"10","author":"E Mohit","year":"2014","unstructured":"Mohit E, Hashemi A, Allahyari M. Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines. Expert Rev Clin Immunol. 2014;10(7):927\u201361.","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"1075_CR18","first-page":"801","volume":"41","author":"X Jing","year":"2019","unstructured":"Jing X, et al. Overexpression of MUC1 predicts poor prognosis in patients with breast cancer. Oncol Rep. 2019;41(2):801\u201310.","journal-title":"Oncol Rep"},{"issue":"3","key":"1075_CR19","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1200\/JCO.2000.18.3.574","volume":"18","author":"S von Mensdorff-Pouilly","year":"2000","unstructured":"von Mensdorff-Pouilly S, et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol. 2000;18(3):574\u201383.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1075_CR20","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2174\/1566524017666170807144946","volume":"17","author":"R Bell","year":"2017","unstructured":"Bell R, Barraclough R, Vasieva O. Gene expression meta-analysis of potential metastatic breast cancer markers. Curr Mol Med. 2017;17(3):200\u201310.","journal-title":"Curr Mol Med"},{"key":"1075_CR21","first-page":"2316237","volume":"2019","author":"H Lu","year":"2019","unstructured":"Lu H, et al. Human mitotic centromere-associated KINESIN IS TARGETED BY MicroRNA 485-5p\/181c and prognosticates poor survivability of breast cancer. J Oncol. 2019;2019:2316237.","journal-title":"J Oncol"},{"issue":"10","key":"1075_CR22","doi-asserted-by":"publisher","first-page":"e25114","DOI":"10.1371\/journal.pone.0025114","volume":"6","author":"FF Costa","year":"2011","unstructured":"Costa FF, et al. Identification of microRNAs as potential prognostic markers in ependymoma. PLoS ONE. 2011;6(10):e25114.","journal-title":"PLoS ONE"},{"issue":"5","key":"1075_CR23","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/j.1365-2559.2010.03686.x","volume":"57","author":"TH Kim","year":"2010","unstructured":"Kim TH, et al. Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology. 2010;57(5):734\u201343.","journal-title":"Histopathology"},{"issue":"7","key":"1075_CR24","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1080\/14737140.2017.1340837","volume":"17","author":"P Merikhian","year":"2017","unstructured":"Merikhian P, et al. MUC1 induces tamoxifen resistance in estrogen receptor-positive breast cancer. Expert Rev Anticancer Ther. 2017;17(7):607\u201313.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"1075_CR25","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/0046-8177(95)90146-9","volume":"26","author":"MA McGuckin","year":"1995","unstructured":"McGuckin MA, et al. Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum Pathol. 1995;26(4):432\u20139.","journal-title":"Hum Pathol"},{"issue":"5","key":"1075_CR26","doi-asserted-by":"publisher","first-page":"6782","DOI":"10.3892\/mmr.2015.4323","volume":"12","author":"H Yuan","year":"2015","unstructured":"Yuan H, et al. Mucin 1 gene silencing inhibits the growth of SMMC-7721 human hepatoma cells through Bax-mediated mitochondrial and caspase-8-mediated death receptor apoptotic pathways. Mol Med Rep. 2015;12(5):6782\u20138.","journal-title":"Mol Med Rep"},{"issue":"12","key":"1075_CR27","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.4161\/cc.9.12.12050","volume":"9","author":"J Fuxe","year":"2010","unstructured":"Fuxe J, Vincent T, Garcia de Herreros A. Transcriptional crosstalk between TGF-beta and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle. 2010;9(12):2363\u201374.","journal-title":"Cell Cycle"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-020-01075-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12282-020-01075-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-020-01075-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T00:53:12Z","timestamp":1614991992000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12282-020-01075-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,6]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1075"],"URL":"https:\/\/doi.org\/10.1007\/s12282-020-01075-2","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,6]]},"assertion":[{"value":"13 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declared that they have no conflicts of interest regarding this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}